ATHE
Price
$4.09
Change
+$0.16 (+4.07%)
Updated
Jun 30, 04:44 PM (EDT)
Capitalization
58.14M
CVM
Price
$2.32
Change
-$0.08 (-3.33%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
12.32M
Interact to see
Advertisement

ATHE vs CVM

Header iconATHE vs CVM Comparison
Open Charts ATHE vs CVMBanner chart's image
Alterity Therapeutics
Price$4.09
Change+$0.16 (+4.07%)
Volume$100
Capitalization58.14M
Cel-Sci
Price$2.32
Change-$0.08 (-3.33%)
Volume$1.99K
Capitalization12.32M
ATHE vs CVM Comparison Chart in %
Loading...
ATHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATHE vs. CVM commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHE is a Buy and CVM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (ATHE: $3.93 vs. CVM: $2.40)
Brand notoriety: ATHE: Not notable vs. CVM: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATHE: 127% vs. CVM: 25%
Market capitalization -- ATHE: $58.14M vs. CVM: $12.32M
ATHE [@Biotechnology] is valued at $58.14M. CVM’s [@Biotechnology] market capitalization is $12.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATHE’s FA Score shows that 0 FA rating(s) are green whileCVM’s FA Score has 0 green FA rating(s).

  • ATHE’s FA Score: 0 green, 5 red.
  • CVM’s FA Score: 0 green, 5 red.
According to our system of comparison, ATHE is a better buy in the long-term than CVM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATHE’s TA Score shows that 4 TA indicator(s) are bullish while CVM’s TA Score has 3 bullish TA indicator(s).

  • ATHE’s TA Score: 4 bullish, 3 bearish.
  • CVM’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, ATHE is a better buy in the short-term than CVM.

Price Growth

ATHE (@Biotechnology) experienced а -6.35% price change this week, while CVM (@Biotechnology) price change was -5.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +32.93%, and the average quarterly price growth was +6.81%.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATHE($58.1M) has a higher market cap than CVM($12.3M). ATHE YTD gains are higher at: 18.834 vs. CVM (-79.995). ATHE has higher annual earnings (EBITDA): -19.88M vs. CVM (-21.96M). ATHE has more cash in the bank: 4.54M vs. CVM (1.92M). ATHE has less debt than CVM: ATHE (106K) vs CVM (10.5M). ATHE (0) and CVM (0) have equivalent revenues.
ATHECVMATHE / CVM
Capitalization58.1M12.3M472%
EBITDA-19.88M-21.96M91%
Gain YTD18.834-79.995-24%
P/E RatioN/AN/A-
Revenue00-
Total Cash4.54M1.92M236%
Total Debt106K10.5M1%
FUNDAMENTALS RATINGS
ATHE vs CVM: Fundamental Ratings
ATHE
CVM
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4196
P/E GROWTH RATING
1..100
10054
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATHE's Valuation (89) in the Biotechnology industry is in the same range as CVM (98). This means that ATHE’s stock grew similarly to CVM’s over the last 12 months.

ATHE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CVM (100). This means that ATHE’s stock grew similarly to CVM’s over the last 12 months.

ATHE's SMR Rating (100) in the Biotechnology industry is in the same range as CVM (100). This means that ATHE’s stock grew similarly to CVM’s over the last 12 months.

ATHE's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for CVM (96). This means that ATHE’s stock grew somewhat faster than CVM’s over the last 12 months.

CVM's P/E Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for ATHE (100). This means that CVM’s stock grew somewhat faster than ATHE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATHECVM
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
85%
MACD
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
72%
N/A
Declines
ODDS (%)
N/A
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
84%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
73%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ULH25.730.09
+0.35%
Universal Logistics Holdings
ES63.360.11
+0.17%
Eversource Energy
OR25.03-0.69
-2.68%
OR Royalties Inc.
AGEN4.76-0.15
-3.05%
Agenus
DFDV16.82-1.12
-6.24%
DeFi Development Corp

ATHE and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATHE has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATHE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATHE
1D Price
Change %
ATHE100%
+0.34%
EYPT - ATHE
54%
Loosely correlated
-7.04%
GLMD - ATHE
31%
Poorly correlated
+1.12%
CVM - ATHE
30%
Poorly correlated
-1.64%
MSCLF - ATHE
28%
Poorly correlated
-7.45%
ENGN - ATHE
28%
Poorly correlated
+0.56%
More

CVM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CVM has been loosely correlated with NRXS. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CVM jumps, then NRXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVM
1D Price
Change %
CVM100%
-1.64%
NRXS - CVM
59%
Loosely correlated
-0.79%
EYPT - CVM
37%
Loosely correlated
-7.04%
MGX - CVM
32%
Poorly correlated
-8.18%
ATHE - CVM
28%
Poorly correlated
+0.34%
AKRO - CVM
27%
Poorly correlated
-0.16%
More